Summary • Ultragenyx Pharmaceutical Inc. stock rises 14.6% to $22.59 amid market reaction to Phase 3 study results.• Phase 3 studies for Setrusumab (UX143) did not meet primary endpoints, causing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback